Search
ASCO 2026: Gilead CMO Dietmar Berger discusses the company's cell therapy and antibody-drug conjugate approaches in oncology, and shares the rationale on four recent acquisitions
On the ADC front, he discusses Trodelvy's role in triple-negative breast cancer and the rationale for acquiring Tubulis for its next generation ADC pipeline. Plus, BCMA CAR-T (the acquisition of Arcellx), treating glioblastoma with CAR-T, and the future of in vivo cell therapy.
May 30
ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline
He discusses the result of the ASCENT-04 study, which was in combination with Keytruda in PD-L1+ patients, and highlights data...
May 31, 2025
Gilead's Dan O'Day on 1Q23 Earnings
BiotechTV's exclusive interview with Gilead Sciences' Chairman & CEO Dan O'Day on the company's Q1 2023 earnings day.
Apr 27, 2023
Kite Pharma's Kristi Shaw talks cell therapy at #JPM23
Kite’s Kristi Shaw discusses BCMA, moving CAR-T into earlier lines of treatment, and focusing on improving auto programs.
Jan 10, 2023
.png){kind=logo}